Header Logo

Connection

Usman Baber to United States

Back to Details
This is a "connection" page, showing publications Usman Baber has written about United States.
Usman Baber
Connection Strength
1.774
United States
  1. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004945.
    View in: PubMed
    Score: 0.102
  2. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.096
  3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. JACC Cardiovasc Interv. 2017 10 23; 10(20):2017-2025.
    View in: PubMed
    Score: 0.092
  4. Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry. Coron Artery Dis. 2016 Sep; 27(6):442-8.
    View in: PubMed
    Score: 0.087
  5. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.086
  6. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.084
  7. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. JACC Cardiovasc Imaging. 2012 Mar; 5(3 Suppl):S53-61.
    View in: PubMed
    Score: 0.063
  8. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011 Feb; 4(1):26-32.
    View in: PubMed
    Score: 0.058
  9. Combined role of reduced estimated glomerular filtration rate and microalbuminuria on the prevalence of peripheral arterial disease. Am J Cardiol. 2009 Nov 15; 104(10):1446-51.
    View in: PubMed
    Score: 0.054
  10. Non-traditional risk factors predict coronary calcification in chronic kidney disease in a population-based cohort. Kidney Int. 2008 Mar; 73(5):615-21.
    View in: PubMed
    Score: 0.047
  11. Educational Experience of Interventional?Cardiology Fellows in the United States?and Canada. JACC Cardiovasc Interv. 2023 02 13; 16(3):247-257.
    View in: PubMed
    Score: 0.034
  12. Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Crit Pathw Cardiol. 2020 06; 19(2):69-74.
    View in: PubMed
    Score: 0.028
  13. Sleep Duration and Cardiovascular Health in a Representative Community Population (from NHANES, 2005 to 2016). Am J Cardiol. 2020 07 15; 127:149-155.
    View in: PubMed
    Score: 0.028
  14. Association between age and readmission after percutaneous coronary intervention for acute myocardial infarction. Heart. 2020 10; 106(20):1595-1603.
    View in: PubMed
    Score: 0.028
  15. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. Clin Res Cardiol. 2020 Jun; 109(6):725-734.
    View in: PubMed
    Score: 0.027
  16. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. Am J Cardiol. 2020 01 15; 125(2):251-257.
    View in: PubMed
    Score: 0.027
  17. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thromb Haemost. 2019 10; 119(10):1704-1711.
    View in: PubMed
    Score: 0.027
  18. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 07 01; 40(25):2070-2085.
    View in: PubMed
    Score: 0.026
  19. Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. J Thromb Thrombolysis. 2019 Jul; 48(1):42-51.
    View in: PubMed
    Score: 0.026
  20. Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2020 04 01; 95(5):885-892.
    View in: PubMed
    Score: 0.026
  21. Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. Int J Cardiol. 2019 07 15; 287:59-61.
    View in: PubMed
    Score: 0.026
  22. Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. Cardiorenal Med. 2019; 9(3):160-167.
    View in: PubMed
    Score: 0.026
  23. Frequency of 30-day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock. Catheter Cardiovasc Interv. 2019 Aug 01; 94(2):E67-E77.
    View in: PubMed
    Score: 0.026
  24. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheter Cardiovasc Interv. 2019 Jul 01; 94(1):53-60.
    View in: PubMed
    Score: 0.026
  25. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 12 07; 39(46):4101-4108.
    View in: PubMed
    Score: 0.025
  26. Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Int J Cardiol. 2019 Jan 15; 275:31-35.
    View in: PubMed
    Score: 0.025
  27. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheter Cardiovasc Interv. 2019 02 15; 93(3):E112-E119.
    View in: PubMed
    Score: 0.025
  28. Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thromb Haemost. 2018 Nov; 118(11):1997-2005.
    View in: PubMed
    Score: 0.025
  29. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.025
  30. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions. J Invasive Cardiol. 2018 07; 30(7):251-255.
    View in: PubMed
    Score: 0.024
  31. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. JACC Cardiovasc Interv. 2018 01 08; 11(1):1-12.
    View in: PubMed
    Score: 0.024
  32. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Can J Cardiol. 2018 03; 34(3):319-329.
    View in: PubMed
    Score: 0.024
  33. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Int J Cardiol. 2017 Nov 01; 246:20-25.
    View in: PubMed
    Score: 0.024
  34. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.023
  35. Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1016-1026.
    View in: PubMed
    Score: 0.023
  36. Impact of pre-existing or new-onset atrial fibrillation on 30-day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheter Cardiovasc Interv. 2017 Nov 15; 90(6):1027-1037.
    View in: PubMed
    Score: 0.023
  37. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.022
  38. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. 2016 Dec 27; 68(25):2733-2744.
    View in: PubMed
    Score: 0.022
  39. Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. Am J Cardiol. 2017 Mar 15; 119(6):881-885.
    View in: PubMed
    Score: 0.022
  40. Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. Am J Cardiol. 2016 Dec 01; 118(11):1661-1668.
    View in: PubMed
    Score: 0.022
  41. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.022
  42. A Simple Disease-Guided Approach to Personalize ACC/AHA-Recommended Statin Allocation in Elderly People: The BioImage Study. J Am Coll Cardiol. 2016 08 30; 68(9):881-91.
    View in: PubMed
    Score: 0.022
  43. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.022
  44. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.021
  45. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.021
  46. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 06; 134(10):e156-78.
    View in: PubMed
    Score: 0.021
  47. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.021
  48. Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study. J Am Coll Cardiol. 2015 Nov 03; 66(18):2053-2055.
    View in: PubMed
    Score: 0.020
  49. Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J. 2016 Jan; 171(1):40-7.
    View in: PubMed
    Score: 0.020
  50. Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). Am J Cardiol. 2015 Jul 01; 116(1):37-42.
    View in: PubMed
    Score: 0.020
  51. Atrial fibrillation and incident end-stage renal disease: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Int J Cardiol. 2015 Apr 15; 185:219-23.
    View in: PubMed
    Score: 0.020
  52. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011 Jul 15; 108(2):227-32.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.